Receive our newsletter – data, insights and analysis delivered to you
  1. News
December 15, 2021updated 07 Jan 2022 8:41am

Hardy Diagnostics to commercialise Cal Poly Covid-19 saliva test

The saliva testing device uses existing reverse transcription quantitative polymerase chain reaction technology.

California Polytechnic State University (Cal Poly) in the US has collaborated with medical device manufacturer Hardy Diagnostics to bring its Covid-19 saliva testing technology to the market.

Developed by the university’s faculty, the new device was originally developed to help streamline on-campus Covid-19 testing for students and employees of the university.

It is developed based on existing reverse transcription quantitative polymerase chain reaction (RT-qPCR) technology.

The device is a strip that allows the collection of a saliva sample from an individual’s mouth in 30 seconds. It is said to be less invasive compared to a nasal swab.

Using the new device, Cal Poly was able to double the tests it runs each day as well as reduce the workload needed to perform the tests.

Cal Poly biological sciences associate professor Nathaniel Martinez said: “When placed in one’s mouth, the device automatically absorbs the exact amount of saliva required for the test and excludes potential contaminants like mucus.

Content from our partners
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 

“Thanks to the improved quality of samples and consistency of sample size, the tests can be run more efficiently.”

With assistance from the Center for Innovation and Entrepreneurship (CIE), the Technology Transfer and Corporate Engagement and Innovation offices at Cal Poly have filed for protection of the patent and identified commercialisation partners for further development of the device.

Cal Poly corporate engagement and innovation associate vice-president Jim Dunning said: “The device was developed and refined for the SARS-CoV-2 virus, but our team quickly realised it could also function as a platform saliva collection device for testing a panel of other viruses in the future.

“We found a fantastic local partner in Hardy Diagnostics to scale this technology for the greatest public good.”

Under the terms of the license deal, Hardy Diagnostics will develop the new saliva-based Covid-19 testing technology to bring it to market.

In April, Hardy Diagnostics launched the Matrix-Assisted Laser Desorption/Ionised Time of Flight instrument in partnership with Autobio.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU